HAE vs MANE
Haemonetics vs Veradermics, Incorporated — AI-powered side-by-side comparison
VS
MANE
Veradermics, Incorporated
69
Buy
| Metric | HAE | MANE |
|---|
| AI Score |
49
|
69
|
| Price |
$108.42
|
$98.41
|
| P/E Ratio |
52.82×
|
-48.05×
|
| ROE |
12.2%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
57.4%
|
0.0%
|
| Debt / Equity |
1.40×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.2
|
35.5
|
| Beta |
0.518
|
1.3492
|
| Expected Upside |
+30.2%
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for HAE versus MANE.
MANE leads by 20 points.
MANE scores 69/100 (Buy) versus HAE at 49/100 (Watch).
HAE Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 1.54) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Debt-to-equity of 1.54 adds balance-sheet risk to the value case — Value
- EPS declining -37.4% YoY despite any revenue growth — Growth
MANE Committee View
100% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is sector concentration is already high (hhi 3063.01). The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- MACD histogram negative -- bearish momentum — Technical